Triple-positive breast carcinoma

Researchers are testing whether adding the drug inavolisib to hormone therapy and the antibody combination trastuzumab plus pertuzumab helps shrink HER2-positive, HR-positive breast tumors before surgery. The trial enrolls 170 patients with early-stage breast cancer that has a PI…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study is testing several different drug combinations in people with advanced ER-positive breast cancer that has stopped responding to prior treatments. The trial is designed like an 'umbrella,' allowing new drug combos to be added as they become available. About 316 particip…

This phase 2 trial is testing whether giving a combination of three drugs—neratinib, an aromatase inhibitor (letrozole or anastrozole), and trastuzumab—before surgery can completely eliminate invasive breast cancer in postmenopausal women with ER-positive, HER2-positive breast ca…

This phase II trial is testing whether adding a new oral drug called culmerciclib to standard anti-HER2 therapy and hormone therapy can help maintain control of advanced breast cancer that is both hormone receptor-positive and HER2-positive. The study enrolls women with metastati…

This clinical trial is testing a combination of three drugs—entinostat, pyrotinib, and endocrine therapy—in people with advanced triple-positive breast cancer (cancer that is both hormone receptor-positive and HER2-positive) whose disease has worsened after prior treatment with t…

This study tests a new drug called fovinaciclib combined with hormone therapy and targeted antibodies in people with early-stage HR-positive/HER2-positive breast cancer. After 6 weeks, doctors check if the tumor is shrinking. If it is, patients continue the same treatment; if not…

This study tests a new drug called elacestrant, combined with two standard biologic therapies, in people with advanced triple positive breast cancer (ER+, PR+, HER2+). The goal is to see if the combination can slow or stop cancer growth. About 50 women aged 18 and older will take…

This Phase 2 trial is testing whether adding the drug dalpiciclib to standard anti-HER2 and hormone therapy can help keep advanced breast cancer from growing. It involves 57 women with HR+/HER2+ metastatic breast cancer whose disease has not worsened after initial treatment. The …

This study tests whether adding hormone therapy to standard chemotherapy and HER2-targeted therapy improves tumor response before surgery in people with HER2-positive breast cancer. About 30 adults with stage II to III disease will participate. The goal is to see if this combinat…

This study tests whether adding a CDK4/6 inhibitor to standard hormone therapy can help prevent breast cancer from coming back in high-risk patients with HR+/HER2+ early breast cancer. About 1,900 women aged 18-70 who have already completed anti-HER2 therapy will be randomly assi…

This phase II trial is testing whether a targeted drug called trastuzumab deruxtecan (Enhertu), given alone or with anastrozole (Arimidex), can eliminate HER2-low, hormone receptor positive breast cancer before surgery. The study will enroll 88 people with early-stage breast canc…

This Phase 3 trial tests whether a combination of trastuzumab and neratinib works better than the standard trastuzumab and pertuzumab for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) who still have small amounts of cancer after initial che…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…